He will receive the medal during Innovation Day 2010 at the Chemical Heritage Foundation (CHF) in Philadelphia on 23 September in front of more than 200 scientific leaders from the chemical and molecular science industries.
‘Ron Breslow combines brilliance in research with great effectiveness in telling the story of the achievements of chemistry to all who will listen,’ said Sunil Kumar, president and ceo of International Specialty Products.
‘He is the central architect of two major areas of research: biomimetic systems and nonbenzenoid aromatic chemistry. His work offers promise of important breakthroughs in the fight against cancer by modulating gene transcription in cancer cells.’
For more than 50 years, Breslow has been a member of the faculty of Columbia University, which he joined after studying at Harvard. He has been active on many levels in the National Academy of Sciences (Chairman of the Chemistry Division 1974–77) and the American Chemical Society (ACS president, 1996; Priestley Medal, 1999).
The SCI Perkin Medal is recognised as the highest honour given for outstanding work in applied chemistry in the US. It commemorates the discovery of the first synthetic dye (the so-called Perkin mauve) by Sir William Henry Perkin in 1856. This discovery was a significant step forward in organic chemistry that led to the birth of a major segment of the chemical industry.
The Perkin Medal was first awarded to Sir William at a banquet held by the SCI in New York in 1906. Since then, more than 100 such awards have been given to notable scientists.
SCI awards Perkin Medal to Ronald Breslow
In recognition of his research into biomimetic systems and nonbenzenoid aromatic chemistry
You may also like
Manufacturing
Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics
Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Formulation meets function: addressing palatability in drug development (part II)
Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations